BioWorld

June 4, 2008

Vertex Sells Royalty Rights to HIV Inhibitors for $160 Million

Vertex Pharmaceuticals Inc. is unloading two HIV protease inhibitors it helped develop in a $160 million deal with GlaxoSmithKline plc in which it agreed to sell rights to future royalties for Lexiva and Agenerase. (BioWorld Today) Read More

New Data Show Avant's Vaccine Doubles Survival in Brain Cancer

IRX Brings in $25M to Advance Lead Cancer Compound, IRX-2

NewCo News: NexBio Cuts Off Influenza Virus from its Entry Route

Gen-Probe Makes Counterbid for Diagnostics Firm Innogenetics

Other News To Note

ASCO Roundup: Incyte Slips on Myelofibrosis Data; ImmunoGen Falls, Too

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...